Intralesional Platelet-Rich Plasma for Treating Chronic Peyronie's Disease: A Single-Center Retrospective Cohort Study.

Background and

Objectives

Peyronie's disease (PD) is a chronic fibrotic disorder of the tunica albuginea causing penile deformity and sexual dysfunction. Platelet-rich plasma (PRP) has been proposed as a regenerative therapy with potential disease-modifying properties, but evidence of its use in chronic PD is scarce. This study evaluated the efficacy and safety of intralesional PRP injections in men with stable PD. Materials and

Methods

A single-center retrospective cohort study was conducted including men with chronic PD treated with three weekly intralesional PRP injections (April 2022-April 2025). Inclusion required curvature stability for ≥6 months and absence of prior PD therapy. The primary outcome was a change in penile curvature at 4 weeks post-treatment. Secondary outcomes included plaque thickness (ultrasound), erectile function (IIEF-5), and safety (Clavien-Dindo grading).

Results

Thirty-six men (mean age 61.2 ± 10.4 years) completed the treatment. Mean penile curvature decreased from 30.5 ± 7.3° to 24.2 ± 8.3° (Δ = -6.3°, 95% CI -7.7 to -5.3; p < 0.001); 25% achieved a ≥10° reduction. Mean plaque thickness declined from 3.25 ± 0.69 mm to 2.91 ± 0.76 mm (Δ = -0.34 mm; p < 0.001). IIEF-5 increased modestly (+1.1; p = 0.142). Only mild, transient adverse events occurred (pain 5.6%, hematoma 2.8%).

Conclusions

Intralesional PRP was safe and yielded statistically significant but modest reductions in penile curvature and plaque thickness in chronic PD. Clinically meaningful improvement occurred in a minority of patients. These findings support keeping PRP investigational pending well-designed randomized controlled trials with standardized protocols and longer follow-up.